Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1966 8
1967 2
1968 3
1969 5
1970 2
1971 6
1972 3
1973 5
1974 3
1975 10
1976 10
1977 10
1978 4
1979 10
1980 7
1981 6
1982 15
1983 7
1984 9
1985 9
1986 16
1987 7
1988 5
1989 9
1990 11
1991 6
1992 9
1993 6
1994 16
1995 8
1996 24
1997 18
1998 9
1999 13
2000 10
2001 8
2002 12
2003 25
2004 21
2005 14
2006 13
2007 10
2008 14
2009 21
2010 8
2011 15
2012 10
2013 10
2014 10
2015 10
2016 7
2017 5
2018 5
2019 8
2020 6
2021 12
2022 9
2023 10

Text availability

Article attribute

Article type

Publication date

Search Results

544 results

Results by year

Filters applied: . Clear all
Page 1
Sutimlimab in Cold Agglutinin Disease.
Röth A, Barcellini W, D'Sa S, Miyakawa Y, Broome CM, Michel M, Kuter DJ, Jilma B, Tvedt THA, Fruebis J, Jiang X, Lin S, Reuter C, Morales-Arias J, Hobbs W, Berentsen S. Röth A, et al. Among authors: miyakawa y. N Engl J Med. 2021 Apr 8;384(14):1323-1334. doi: 10.1056/NEJMoa2027760. N Engl J Med. 2021. PMID: 33826820 Clinical Trial.
The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.
Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon SS, Kavanagh D, Haller H; 311 Study Group. Rondeau E, et al. Among authors: miyakawa y. Kidney Int. 2020 Jun;97(6):1287-1296. doi: 10.1016/j.kint.2020.01.035. Epub 2020 Mar 6. Kidney Int. 2020. PMID: 32299680 Free article. Clinical Trial.
Erratum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D, Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment" Kidney Int. 2020;97:1287-1296.
Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon SS, Kavanagh D, Haller H; 311 Study Group. Rondeau E, et al. Among authors: miyakawa y. Kidney Int. 2020 Dec;98(6):1621. doi: 10.1016/j.kint.2020.11.001. Kidney Int. 2020. PMID: 33276869 Free article. No abstract available.
Corrigendum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment." Kidney Int. 2020;97:1287-1296.
Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon SS, Kavanagh D, Haller H; 311 Study Group. Rondeau E, et al. Among authors: miyakawa y. Kidney Int. 2021 May;99(5):1244. doi: 10.1016/j.kint.2021.03.008. Kidney Int. 2021. PMID: 33892867 No abstract available.
Classifying hepatitis C virus genotypes.
Miyakawa Y, Okamoto H, Mayumi M. Miyakawa Y, et al. Mol Med Today. 1995 Apr;1(1):20-5. doi: 10.1016/1357-4310(95)80015-8. Mol Med Today. 1995. PMID: 9415133 Review.
Genetic variability in hepatitis B viruses.
Kidd-Ljunggren K, Miyakawa Y, Kidd AH. Kidd-Ljunggren K, et al. Among authors: miyakawa y. J Gen Virol. 2002 Jun;83(Pt 6):1267-1280. doi: 10.1099/0022-1317-83-6-1267. J Gen Virol. 2002. PMID: 12029141 Review.
544 results